Results of the PRESTOCON preclinical trial are in
Results of the PRESTOCON preclinical trial are in
The results of the PRESTOCON preclinical trial have demonstrated that Panax ginseng and Gingko biloba extracts have a well-documented safety profile and are well tolerated for the treatment of moderate-to-severe disease.
In addition, the trial provided useful insights into the application of Panax ginseng (G115) and Gingko biloba (GK501) as novel and natural therapeutic intervention for the treatment of cognitive-related diseases.
These findings support the idea that the combination may become a valid and safe therapeutic intervention in the treatment of neurological disorders.
Robert Hendriks MD
Chief Executive Officer, SFI Health
Learn
Research is important, and we want to share it. Our articles distill the complex research and offer expert analysis on the microbiome, brain health and wellbeing.
The 5 worst habits for your brain
Your brain is responsible for everything you do. It processes information, stores memories, and shapes who you are. Yet, many of us unknowingly engage in daily habits that can damage...
Read more
What is brain fog and how does it affect your daily life?
‘Brain fog’ isn’t just a buzzword: it’s a frustrating reality for many. Researchers define it as ‘transient cognitive dysfunction', but most of us know it as mental sluggishness.
Read more
SFI Health branded products packed locally in South Africa
Locally packed products increases SFI Health South Africa’s ability to offer greater flexibility in pack sizes, ensuring a product portfolio that aligns more closely with the needs of South African...
Read more